When we determined the anti-SARS-CoV-2 activity in two additional cell lines: (i) HeLa-ACE2-TMPRSS2 cells27 originally derived from a human cervical cancer cell line, and (ii) A549-ACE2-TMPRSS2 cells derived from a human adenocarcinomic alveolar-basal epithelial line, both of which were rendered to express human ACE2 and TMPRSS2, TKB245 exerted potent activity against SARS-CoV-2TWK521 with EC50 values of 0.021 and 0.0027 μM, respectively. This evidence concerns the gene ACE2 and cervical carcinoma.